Latest Entrant To UK Early Access Scheme Will Help Lung Cancer Patients
This article was originally published in SRA
Executive Summary
The latest medicine to enter the UK's early access to medicines scheme (EAMS) is AstraZeneca UK Ltd's lung cancer drug osimertinib, which has just gained a scientific opinion from the Medicines and Healthcare products Regulatory Agency under the EAMS and can now be made available to UK patients while it awaits EU marketing approval1.